Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial.
VaccineSep 17, 2026 (epub)
Clinical ResearchInfectious Diseases
Nutchaya Laoharattanahirun, Sasisopin Kiertiburanakul, Kobporn Boonnak et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the immunogenicity and safety of high-dose (HD) versus standard-dose (SD) quadrivalent inactivated influenza vaccine in patients living with HIV. Among 103 participants, the HD group achieved a significantly higher seroprotection rate of 61.5% compared to 39.2% in the SD group (p = 0.02), with no increase in adverse events.
Key findings
- The HD group had a seroprotection rate of 61.5% compared to 39.2% in the SD group (p = 0.02).
- For the A/H3N2 strain, seroprotection was 76.9% in the HD group versus 52.9% in the SD group (p = 0.01).
- Adverse events were reported in 55.8% of HD and 58.8% of SD recipients, with no severe events observed.
Why it matters
Influenza poses significant health risks for individuals living with HIV, and enhancing vaccine efficacy could improve their protection. This study suggests that high-dose vaccination may be a more effective strategy in this vulnerable population.